Concord Biotech Ltd's Q3FY25 Quarterly Results

Result Summary

• Concord Biotech Ltd reported a 19.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.0%.
• Its expenses for the quarter were down by 14.6% QoQ and up 7.2% YoY.
• The net profit decreased 20.7% QoQ and decreased 2.1% YoY.
• The earnings per share (EPS) of Concord Biotech Ltd stood at 7.3 during Q3FY25.

Financial Statments for Q3FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Concord Biotech Ltd is a company primarily engaged in the biotechnology sector. It focuses on the development, production, and marketing of biopharmaceutical products. The company's product portfolio typically includes a range of therapeutic enzymes, immunosuppressants, and oncology products. Concord Biotech operates in a highly specialized industry characterized by intensive research and development activities. As of the latest available data, there is no additional information about recent major developments or strategic initiatives undertaken by the company. Hence, detailed updates regarding the company's strategic direction or partnerships are not available.

Revenue

In the third quarter of the fiscal year 2025, Concord Biotech Ltd reported a total income of ₹258.95 crores. This represents a 19.1% decline from the previous quarter (Q2FY25), where total income stood at ₹320.21 crores. However, compared to the same quarter in the previous fiscal year (Q3FY24), the company experienced a 4.0% increase in total income, which was then ₹248.98 crores. The quarterly fluctuation indicates variability in revenue streams, while the year-over-year growth suggests a general upward trend over the longer term.

Profitability

Concord Biotech's profitability metrics for Q3FY25 show a profit before tax of ₹99.32 crores, which reflects a 25.5% decrease from the previous quarter (Q2FY25) when it was ₹133.29 crores. Compared to the same quarter last year (Q3FY24), there is a slight decline of 0.8% from a profit before tax of ₹100.08 crores. The profit after tax for Q3FY25 is ₹75.92 crores, down by 20.7% from the previous quarter's ₹95.74 crores and a 2.1% decrease from ₹77.57 crores in Q3FY24. Earnings per share also declined to ₹7.30 in Q3FY25 from ₹9.20 in Q2FY25 and ₹7.40 in Q3FY24, showing similar trends in profitability as other metrics.

Operating Metrics

The total expenses reported by Concord Biotech in Q3FY25 amounted to ₹159.63 crores, which is a 14.6% reduction from the previous quarter's expenses of ₹186.91 crores. However, when compared to the same quarter in the previous year, there is a 7.2% increase from ₹148.91 crores. The tax paid in Q3FY25 was ₹25.23 crores, showing a 27.1% decrease from ₹34.59 crores in Q2FY25, and a 1.2% reduction compared to ₹25.53 crores in Q3FY24. These metrics highlight changing expenditure patterns along with taxation adjustments over the periods analyzed. Key financial ratios such as P/E ratio, debt-to-equity ratio, and current ratio are not calculable with the provided data.